000650.SZ
仁和药业
SZSE · Healthcare · C 制造业 · CN
CNY 5.34
−0.56%Year over year
Reported trailing growth
- Revenue
- -3.7%
- EBITDA
- —
- EBIT
- -13.1%
- EPS
- -22.9%
- Free cash flow
- +149.0%
- Operating cash flow
- +52.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -11.8%
- EBITDA
- -9.9%
- EBIT
- -11.3%
- Net income
- -11.9%
- EPS
- -11.9%
- Free cash flow
- -9.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026